Price movement over the last 24 hours
Air Products & Chemicals, Inc. vs Johnson & Johnson — how do they compare? Air Products & Chemicals, Inc. trades at $302.41 (market cap $66.70B), while Johnson & Johnson trades at $257.48 (market cap $618.61B). The key difference: Johnson & Johnson is far larger — about 9.3× Air Products & Chemicals, Inc.'s market cap, and Air Products & Chemicals, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| APD | JNJ | |
|---|---|---|
Market Cap | $66.70B | $618.61B |
Sector | Basic Materials | Health |
52-Week High | $314.19 | $267.24 |
52-Week Low | $230.42 | $155.17 |
Enterprise Value | $84.11B | $651.54B |
Dividend Yield | 2.42% | 2.09% |
Volume | — | 6,156,228 |
Signals from Pluang's Aura AI — not financial advice
APD trades at $299.53, up 1.24% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings beats and strategic project exits, like the Louisiana Clean Energy Complex, have boosted investor confidence. The company maintains solid profitability margins but faces pressure from a negative net income in 2025 due to a pre-tax charge. Cash flow trends show volatility, with significant investing outflows for growth initiatives.
The outlook is positive with a consensus price target of $324.89, implying ~8% upside. Risks include high debt levels, execution on new projects, and macroeconomic sensitivity. Long-term growth is supported by renewable energy investments, but near-term profitability recovery is key for sustained gains.
Johnson & Johnson (JNJ) trades at $256.98, down 0.82% today, with a bullish technical signal from moving averages and a consensus analyst price target of $268.50. The company reported strong Q1 2026 EPS of $2.70, beating expectations, and maintains robust profitability with a net income margin of 21.83%. Recent news highlights dividend growth strategies and comparisons with peers like AbbVie, while cash flow trends show operational strength despite negative net cash flow in 2025.
JNJ presents a stable investment opportunity with consistent earnings beats and a solid dividend, but faces risks from rising debt levels and competitive pressures. The stock's current valuation metrics, including a P/E of 29.78, suggest it is fairly valued with moderate upside potential based on analyst targets. Investors should weigh the company's strong fundamentals against macroeconomic and sector-specific headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →